Fidelis Capital Partners LLC Grows Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Fidelis Capital Partners LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 4.2% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 29,973 shares of the company’s stock after purchasing an additional 1,213 shares during the quarter. Fidelis Capital Partners LLC’s holdings in Johnson & Johnson were worth $4,552,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of JNJ. Wealth Group Ltd. acquired a new position in Johnson & Johnson in the third quarter valued at approximately $213,000. Swedbank AB boosted its holdings in shares of Johnson & Johnson by 5.3% in the 3rd quarter. Swedbank AB now owns 2,215,108 shares of the company’s stock valued at $358,980,000 after buying an additional 111,570 shares in the last quarter. Donaldson Capital Management LLC grew its position in shares of Johnson & Johnson by 2.1% in the 3rd quarter. Donaldson Capital Management LLC now owns 343,944 shares of the company’s stock valued at $55,740,000 after buying an additional 7,092 shares during the last quarter. Cortland Associates Inc. MO raised its stake in Johnson & Johnson by 21.2% during the 3rd quarter. Cortland Associates Inc. MO now owns 2,008 shares of the company’s stock worth $325,000 after acquiring an additional 351 shares in the last quarter. Finally, Intact Investment Management Inc. lifted its position in Johnson & Johnson by 23.3% in the third quarter. Intact Investment Management Inc. now owns 91,809 shares of the company’s stock valued at $14,879,000 after acquiring an additional 17,320 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on JNJ. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Barclays increased their price objective on Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a report on Tuesday, January 28th. Leerink Partners lowered their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Raymond James reduced their price target on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Finally, Wolfe Research started coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 price objective on the stock. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $170.67.

Insider Buying and Selling at Johnson & Johnson

In other news, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Mark A. Weinberger bought 1,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $165.48 on Wednesday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The firm has a market capitalization of $398.41 billion, a P/E ratio of 24.88, a PEG ratio of 2.56 and a beta of 0.52. The company’s fifty day moving average is $151.73 and its two-hundred day moving average is $156.12.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Johnson & Johnson’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period last year, the business posted $2.29 EPS. Analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were paid a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.00%. Johnson & Johnson’s payout ratio is 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.